02696.HK
Shanghai Henlius Biotech, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 70.10
+1.52%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
25.8x
EV/EBITDA
29.1x
Market Cap
HKD 38.10B
MomentumView details →
1D Return
+1.52%
YTD Return
+22.87%
RSI (14)
56.7
ValuationView details →
P/E (Fwd)
25.8x
EV/EBITDA
29.1x
Market Cap
HKD 38.10B
RSI (14)
56.7
MomentumView details →
1D Return
+1.52%
YTD Return
+22.87%
Similar companies
Latest newsMore news →
Alligator Bioscience announced it is abandoning independent development of its lead cancer drug mitazalimab, shifting to a leaner model focused on its royalty interest in HLX22, and reducing staff and operating costs.9d agoGIC Private Limited increased its stake in Shanghai Henlius Biotech (02696.HK) to 5.03% by buying 232,200 H-shares at an average price of HK$68.6666 per share on August 21, 2026.9d agoShanghai Henlius Biotech (02696) announced that the first patient has been dosed in a Phase 1 clinical study of its self-developed HLX3902 injection for metastatic castration-resistant prostate cancer and other advanced solid tumors in China (excluding Hong Kong, Macau, and Taiwan).37d ago